Literature DB >> 32858472

Chemotherapy and chemo-resistance in nasopharyngeal carcinoma.

Shuzhen Guan1, Jinrui Wei2, Lingkun Huang1, Lichuan Wu3.   

Abstract

Nasopharyngeal carcinoma (NPC) is closely associated with Epstein-Barr virus (EBV) and occurs frequently in the south of China and Southeast Asian countries. Concurrent chemo-radiotherapy is one of the main treatments for NPC. Although, the combined treatment of chemo-radiotherapy produces a satisfying survival rate, the chemo-resistance arises as a big obstacle in curing recurrent NPC patients. The acquirement of chemo-resistance is usually along with a poor prognosis. So far, the mechanism of chemo-resistance in NPC has not been fully elucidated and there have not been a comprehensive review on this issue. Thus, it is of great significance to summarize the mechanisms involved in NPC chemo-resistance. In this review, the importance and limitations of chemotherapy and the mechanisms of chemo-resistances in NPC were discussed.
Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Chemo-resistance; Chemotherapy; Epstein-Barr virus; Nasopharyngeal carcinoma

Mesh:

Year:  2020        PMID: 32858472     DOI: 10.1016/j.ejmech.2020.112758

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  17 in total

1.  CDKN2B-AS1 promotes the proliferation, clone formation, and invasion of nasopharyngeal carcinoma cells by regulating miR-98-5p/E2F2 axis.

Authors:  Zhengwen Li; Xiaojing Cai; Wentao Zou; Jiaxiong Zhang
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

2.  A systematic analysis in efficacy and safety of nimotuzumab combined with chemoradiotherapy in treatment of advanced nasopharyngeal carcinoma.

Authors:  Yunqin Sun; Yaofeng Wang; Liping Guan
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-09-02       Impact factor: 3.236

Review 3.  Extracellular Vesicles in the Progression and Therapeutic Resistance of Nasopharyngeal Carcinoma.

Authors:  Yunhan Shan; Peijun Zhou; Qin Zhou; Lifang Yang
Journal:  Cancers (Basel)       Date:  2022-05-04       Impact factor: 6.575

4.  Parotid Gland Stem Cell Preservation during Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma: Dosimetric Analysis and Feasibility.

Authors:  Lirong Zheng; Qiaoli Mei; Yuxiang Gao; Fenglei Du; Lin Xiao; Gangfeng Wu
Journal:  J Oncol       Date:  2022-07-12       Impact factor: 4.501

5.  Novel Plasma Proteomic Biomarkers for Early Identification of Induction Chemotherapy Beneficiaries in Locoregionally Advanced Nasopharyngeal Carcinoma.

Authors:  Shan-Qiang Zhang; Su-Ming Pan; Shu-Zhen Lai; Hui-Jing Situ; Jun Liu; Wen-Jie Dai; Si-Xian Liang; Li-Qing Zhou; Qi-Qi Lu; Pei-Feng Ke; Fan Zhang; Hai-Bin Chen; Ji-Cheng Li
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

6.  Gemcitabine Combined with Cisplatin Has a Better Effect in the Treatment of Recurrent/Metastatic Advanced Nasopharyngeal Carcinoma.

Authors:  Qiao Yang; Yue Hua Nie; Man Bo Cai; Zhi Min Li; Hong Bo Zhu; Ye Ru Tan
Journal:  Drug Des Devel Ther       Date:  2022-04-26       Impact factor: 4.319

7.  Design, Synthesis, Molecular Docking, and Tumor Resistance Reversal Activity Evaluation of Matrine Derivative with Thiophene Structure.

Authors:  Jinrui Wei; Yuehui Liang; Lichuan Wu
Journal:  Molecules       Date:  2021-01-14       Impact factor: 4.411

Review 8.  The Role of Genetic Pathways in the Development of Chemoradiation Resistance in Nasopharyngeal Carcinoma (NPC) Patients.

Authors:  Norhafiza Mat Lazim; Che Ismail Che Lah; Wan Khairunnisa Wan Juhari; Sarina Sulong; Bin Alwi Zilfalil; Baharudin Abdullah
Journal:  Genes (Basel)       Date:  2021-11-21       Impact factor: 4.096

9.  Cullin 4A/protein arginine methyltransferase 5 (CUL4A/PRMT5) promotes cell malignant phenotypes and tumor growth in nasopharyngeal carcinoma.

Authors:  Xiuying Sun; Jinhui Zhou; Zhicun Zhang
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

10.  Performance of Plasma HSP90α, Serum EBV VCA IgA Antibody and Plasma EBV DNA for the Diagnosis and Prognosis Prediction of Nasopharyngeal Carcinoma.

Authors:  Qian Ye; Junying Guo; Yansong Chen; Zhaolei Cui; Yan Chen
Journal:  Cancer Manag Res       Date:  2021-07-20       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.